PF-08634404 for Hepatocellular carcinoma (unresectable, locally advanced or metastatic)

Inclusion criteria

• {"criterion_text":"- 1. 18 years of age or older (or the minimum age of consent in accordance with local regulations) at screening.\n- 10. Participants with HCV infection (as characterized by the presence of detectable anti-HCV antibody and detectable HCV RNA) must be managed per local institutional practice.\n- 11. The participant must provide written informed consent.\n- 2. Participants must meet the following criteria: a) Locally advanced or metastatic HCC with diagnosis confirmed by histology/ cytology or clinically by AASLD35 criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis. b) Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locorregional therapies. For participants who progressed after locoregional therapy for HCC, locoregional therapy must have been completed ≥28 days prior to the baseline scan for the current study.\n- 3. Participants must have at least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.\n- 4. Have sufficient tumor tissue available, either paraffin block or slides from a core or excisional biopsy (cytology samples including cell blocks prepared from FNA biopsies and biopsies containing bone, are not adequate).\n- 5. No prior systemic therapy for HCC.\n- 6. ECOG PS score of 0 or 1.\n- 7. Child-Pugh Class - (see Appendix 9 Section 10.9.1).\n- 8. Adequate organ function determined by meeting the following criteria: a) Participants must meet the hematologic criteria below without the use of transfusions or growth factors (platelet or red blood cell transfusions, TPO, EPO, G-CSF, IL-11, etc.) within 7 days prior to baseline laboratory tests.\n- 9. Participants with HBV infection (as characterized by positive HBsAg or detectable HBV DNA) must be treated with antiviral therapy, per institutional practice, to ensure adequate viral suppression (HBV DNA ≤500 IU/mL) prior to enrollment. Note: HBV-positive participants must remain on antiviral therapy for the study duration."}

Exclusion criteria

• {"criterion_text":"- 1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.\n- 10. Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose including but not limited to the following: a) Unstable angina b) Myocardial infarction c) Uncontrolled or significant arrhythmia (including sustained ventricular tachyarrhythmia and ventricular fibrillation), untreated serious conduction system abnormalities (eg, bifascicular block [defined as right bundle branch and left anterior or posterior hemiblock], 3rd degree AV block) d) Coronary/peripheral artery bypass graft e) Transient ischemic attack, cerebrovascular accident, cerebral infarction (excluding lacunar infarction), or cerebral hemorrhage f) Symptomatic congestive heart failure or symptoms consistent with NYHA Functional Class II or higher g) Decompensated liver cirrhosis h) Nephrotic syndrome i) Uncontrolled diabetes defined as HbA1c ≥8.0% or HbA1c between 7.0% and 8.0% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained (or poor compliance with hypoglycemic medications) j) Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg, or poor compliance with antihypertensive medications) k) Arterial thromboembolic event or Grade ≥3 venous thromboembolic eventas specified in CTCAE 5.0. l) Hypertensive crisis m) Hypertensive encephalopathy n) Baseline QTcF interval >480 msec. If QTcF exceeds 480 msec, the ECG is to be repeated twice and the average of the 3 QTcF values should be used to determine the participant’s eligibility. Computer-interpreted ECGs with abnormal findings should be overread by an investigator physician experienced in reading ECGs before excluding participants.\n- 11. Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study; minor local surgery (excluding peripherally inserted central catheter placement and implantable central venous port placement) within 3 days prior to the first dose. Participants must have recovered adequately from the toxicity or complications from the surgery prior to starting study intervention.\n- 12. History of severe bleeding tendency or coagulation dysfunction, such as presence of clinically significant bleeding symptoms within 1 month prior to the first dose, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing up or expectorating ≥1/2 teaspoon of fresh blood or small blood clots or coughing up blood without sputum; participants with blood-streaked sputum are allowed to be enrolled), or epistaxis (excluding minor nosebleeds and blood-tinged nasal discharge).\n- 13. History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.\n- 14. Participants with acute, chronic or symptomatic infections including: a) Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of administration of first dose of study intervention (other than for HIV, HBV or HCV treatment). Routine antimicrobial prophylaxis is permitted. b) Known seropositivity of HIV, except for participants with controlled HIV infection on a stable regimen of ART (CD4+ count >200/mm3 and viral load of <400 copies/mL). The investigator will ensure the ART does not result in substantial interactions with study or concomitant medications. Note: All participants will be tested for HIV locally prior to randomization and if not in contradiction with local legislation. c) Participants with known active TB. Participants suspected of active TB are required to undergo clinical evaluation to rule out the condition.\n- 15. Participants with history of primary immunodeficiency.\n- 16. Known to have a history of a severe allergy to any component of the study intervention, or a history of severe allergic reaction to chimeric or humanized antibody.\n- 17. Previous treatment with anti-VEGF inhibitor or immunotherapy, including but not limited to immune checkpoint inhibitors (eg, PD-(L)-1 antibodies, anti-CTLA-4 antibodies).\n- 18. Prior radiotherapy to a non-liver region ≤2 weeks of first dose of study intervention.\n- 19. Other Prior/Concomitant Therapies: a) Use of therapeutic oral or parenteral anticoagulants or thrombolytic agents within 10 days prior to the first dose of study intervention (excluding prophylactic use). Prophylactic use of low molecular weight heparin is permitted. b) Use of chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole, clopidogrel, or similar agents within 10 days prior to the first dose of study intervention. Once daily low-dose aspirin (≤100 mg/day) is permitted. c) Use of any live or attenuated live vaccine within 4 weeks prior to the first dose of study intervention, or planned vaccination of any live or attenuated live vaccine during the study d) Current use of a high-dose systemic corticosteroids (>10 mg daily prednisone or equivalent) or other immune suppressant or has a condition requiring a chronic highdose steroid or immune suppressant. e) Use of any prohibited concomitant medication(s) within 21 days of the first dose of study intervention or unwillingness or inability to use a required concomitant medication(s). Refer to Section 6.9 for additional details.\n- 2. Participants with any of the following: a) - b) - Note: Participants must undergo an EGD, and all sizes of varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Participants who have undergone an EGD within 6 months prior to initiation of study treatment do not need to repeat the procedure. c) Moderate or severe ascites d) Active or history of hepatic encephalopathy within 6 months prior to the first dose.\n- 20. Previous administration of an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.\n- 21. Investigator site staff directly involved in the conduct of the study and their family members, site staff, otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.\n- 22. Breastfeeding female participants, individuals of childbearing potential, and male participants who are unwilling to follow pregnancy measures.\n- 3. Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be enrolled if all of the following are met: a) CNS metastases have been clinically stable with no evidence of clinical or radiographic disease progression for ≥14 days after completion of definitive radiotherapy and/or surgery and prior to study intervention. b) The participant has not required steroids for brain metastasis symptom management for 7 days prior to first dose of study intervention. c) Participants with asymptomatic brain metastases of longest diameter <1 cm permitted if all the following criteria are met:  absence of neurological symptoms,  no need for corticosteroids, and  brain metastasis has no evidence of edema or hemorrhagic features\n- 4. Clinically significant risk of hemorrhage or fistula including but not limited to the following:  Significant tumor necrosis or cavitation,  The investigator deems that participation in the study poses a risk of hemorrhage;  Tumor invasion or compression of surrounding critical organs (such as aorta, heart and pericardium, superior vena cava, trachea, and esophagus) or a risk of developing tracheoesophageal or pleuroesophageal fistula;  Mediastinal lymph node metastasis with invasion of the trachea or main bronchi. If centrally located mediastinal masses (<30 mm from the carina) identified by CT scan or chest x-ray, CT scan with intravenous contrast or MRI within 21 days prior to randomization must exclude major airway or blood vessel invasion by tumor.\n- 5. Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year OS ≥90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.\n- 6. Unresolved toxicities from prior antitumor therapy, defined as not having recovered to NCI CTCAE v5.0 Grade 0 or 1, or to levels specified in the inclusion/exclusion criteria, with the exception of alopecia. Participants who experience irreversible toxicity that is not expected to worsen with continued administration of the study intervention (eg, hearing loss) may be enrolled in the study after consultation with the medical monitor. Participants with long-term toxicity from radiotherapy that is deemed irreversible by the investigator may be enrolled in the study after consultation with the medical monitor.\n- 7. History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n- 8. Participants with active autoimmune diseases requiring systemic treatment within the past 2 years (ie, with use of disease-modifying agents, corticosteroids or immunosuppressive drugs) a) Replacement therapy (eg, thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic disease modifying treatment and is allowed. b) Participants with vitiligo, psoriasis, type 1 diabetes mellitus (if not excluded per Exclusion Criterion #10), or resolved childhood asthma/atopy are allowed. c) Participants requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections are allowed. d) Participants with Sjögren’s syndrome are allowed.\n- 9. Evidence of non-infectious or drug-induced ILD or pneumonitis that:  Was previously diagnosed and was managed with parenteral steroids for any duration or oral steroids for >6 weeks  Had onset during or after treatment with immunotherapy, improved or resolved, then recurred after immunotherapy rechallenge, or;  Is currently diagnosed and managed with systemic therapy, or  Is suspected on radiologic imaging at screen"}

Primary endpoints

• {"endpoint_text":"- Phase 1b (Safety Run-In): AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.","definition_or_measurement_approach":"Adverse events characterised by type, frequency, severity graded by NCI CTCAE v5.0, timing, seriousness and relationship to study intervention."}
• {"endpoint_text":"- DLTs","definition_or_measurement_approach":""}
• {"endpoint_text":"- Phase 2 (Dose Optimization/Expansion): Confirmed ORR per RECIST 1.1 by investigator.","definition_or_measurement_approach":"Objective response rate confirmed per RECIST 1.1 assessed by investigator."}
• {"endpoint_text":"- AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.","definition_or_measurement_approach":"Adverse events characterised by type, frequency, severity graded by NCI CTCAE v5.0, timing, seriousness and relationship to study intervention."}

Secondary endpoints

• {"endpoint_text":"- Phase 1b (Safety Run-In): Confirmed ORR per RECIST 1.1 by investigator","definition_or_measurement_approach":"Objective response rate per RECIST 1.1 by investigator."}
• {"endpoint_text":"- DOR per RECIST 1.1 by investigator","definition_or_measurement_approach":"Duration of response per RECIST 1.1 by investigator."}
• {"endpoint_text":"- PFS per RECIST 1.1 by investigator","definition_or_measurement_approach":"Progression-free survival per RECIST 1.1 by investigator."}
• {"endpoint_text":"- OS","definition_or_measurement_approach":"Overall survival (no further definition provided)."}
• {"endpoint_text":"- Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.","definition_or_measurement_approach":"Laboratory abnormalities graded by NCI CTCAE v5.0 and described by type, frequency, severity and timing."}
• {"endpoint_text":"- Predose and/or postdose concentrations of PF-08634404","definition_or_measurement_approach":"Pharmacokinetic measurements of PF-08634404 predose and/or postdose concentrations."}
• {"endpoint_text":"- Incidence of ADA against PF-08634404","definition_or_measurement_approach":"Immunogenicity: incidence of anti-drug antibodies against PF-08634404."}
• {"endpoint_text":"- Phase 2 (Dose Optimization/Expansion): DOR per RECIST 1.1 by investigator","definition_or_measurement_approach":"Duration of response per RECIST 1.1 by investigator."}
• {"endpoint_text":"- PFS per RECIST 1.1 by investigator","definition_or_measurement_approach":"Progression-free survival per RECIST 1.1 by investigator."}
• {"endpoint_text":"- OS","definition_or_measurement_approach":"Overall survival (no further definition provided)."}
• {"endpoint_text":"- Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.","definition_or_measurement_approach":"Laboratory abnormalities graded by NCI CTCAE v5.0 and described by type, frequency, severity and timing."}
• {"endpoint_text":"- Predose and/or postdose concentrations of PF-08634404.","definition_or_measurement_approach":"Pharmacokinetic measurements of PF-08634404 predose and/or postdose concentrations."}
• {"endpoint_text":"- Incidence of ADA against PF-08634404.","definition_or_measurement_approach":"Immunogenicity: incidence of anti-drug antibodies against PF-08634404."}

Germany

Earliest CTIS Part Ii Submission Date

17-03-2026

Latest Decision Or Authorization Date

29-04-2026

Processing Time Days

43

Number Of Sites

6

Number Of Participants

20

Spain

Earliest CTIS Part Ii Submission Date

06-03-2026

Latest Decision Or Authorization Date

29-04-2026

Processing Time Days

54

Number Of Sites

4

Number Of Participants

28

France

Earliest CTIS Part Ii Submission Date

22-01-2026

Latest Decision Or Authorization Date

29-04-2026

Processing Time Days

97

Number Of Sites

4

Number Of Participants

10

Italy

Earliest CTIS Part Ii Submission Date

25-02-2026

Latest Decision Or Authorization Date

29-04-2026

Processing Time Days

63

Number Of Sites

6

Number Of Participants

20

Primary sponsor

Full Name

Pfizer Inc.

Organisation Type

Pharmaceutical company

Country Of Registered Address

United States

Contract research organisations

Name

Bioclinica Inc.

Responsibilities

Imaging

Name

Icon Clinical Research Limited

Responsibilities

Central Lab

Name

IQVIA Limited

Responsibilities

ePRO

Name

Parexel

Responsibilities

Ancillary Supplies & IP Destruction

Third parties

• {"country":"United States","full_name":"Bioclinica Inc.","duties_or_roles":"Imaging","organisation_type":"Laboratory/Research/Testing facility"}
• {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"Central Lab","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Scout Clinical","duties_or_roles":"Patient Compensation","organisation_type":"Hospital/Clinic/Other health care facility"}
• {"country":"Luxembourg","full_name":"TecEx","duties_or_roles":"IOR","organisation_type":"Industry"}
• {"country":"United Kingdom","full_name":"IQVIA Limited","duties_or_roles":"ePRO","organisation_type":"Pharmaceutical company"}
• {"country":"United States","full_name":"Parexel","duties_or_roles":"Ancillary Supplies & IP Destruction","organisation_type":"Industry"}